Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Masked polycythemia vera: analysis of a single center cohort of 2480 red cell masses.

Maslah N, Soret J, Dosquet C, Vercellino L, Belkhodja C, Schlageter MH, Cassinat B, Kiladjian JJ, Chomienne C, Giraudier S.

Haematologica. 2020 Mar;105(3):e95-e97. doi: 10.3324/haematol.2018.215582. Epub 2019 Aug 14. No abstract available.

2.

Autologous111 Indium-oxinate-labelled platelet sequestration study in patients with immune thrombocytopenia treated by thrombopoietin receptor-agonists.

Mahevas M, Van Eeckhoudt S, Moulis G, Limal N, Languille L, Bierling P, Dossier A, Duriez F, Galicier L, Morin AS, Tamburini J, Chaoui D, Bouscary D, Jijakli AAL, Khellaf M, Vaida I, Michel M, Vercellino L, Jaddi H, Yollant A, Dosquet C, Godeau B, Chomienne C.

Br J Haematol. 2019 Aug;186(3):e44-e47. doi: 10.1111/bjh.15890. Epub 2019 Apr 4. No abstract available.

PMID:
30950041
3.

When hemolysis masks polycythemia vera.

Derrieux C, Jeandel R, Martin A, Dosquet C, Cassinat B, Fouillard L.

Clin Case Rep. 2019 Jan 28;7(3):438-441. doi: 10.1002/ccr3.1776. eCollection 2019 Mar.

4.

[Towards a personalized pretransplantation conditioning in patients with myelodysplastic syndromes].

Goulard M, Dosquet C, Chomienne C.

Med Sci (Paris). 2018 Jan;34(1):9-11. doi: 10.1051/medsci/20183401002. Epub 2018 Jan 31. French. No abstract available.

5.

Role of the microenvironment in myeloid malignancies.

Goulard M, Dosquet C, Bonnet D.

Cell Mol Life Sci. 2018 Apr;75(8):1377-1391. doi: 10.1007/s00018-017-2725-4. Epub 2017 Dec 8. Review.

6.

Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study.

Ianotto JC, Chauveau A, Boyer-Perrard F, Gyan E, Laribi K, Cony-Makhoul P, Demory JL, de Renzis B, Dosquet C, Rey J, Roy L, Dupriez B, Knoops L, Legros L, Malou M, Hutin P, Ranta D, Benbrahim O, Ugo V, Lippert E, Kiladjian JJ.

Haematologica. 2018 Mar;103(3):438-446. doi: 10.3324/haematol.2017.181297. Epub 2017 Dec 7.

7.

Preclinical modeling of myelodysplastic syndromes.

Rouault-Pierre K, Mian SA, Goulard M, Abarrategi A, Di Tulio A, Smith AE, Mohamedali A, Best S, Nloga AM, Kulasekararaj AG, Ades L, Chomienne C, Fenaux P, Dosquet C, Mufti GJ, Bonnet D.

Leukemia. 2017 Dec;31(12):2702-2708. doi: 10.1038/leu.2017.172. Epub 2017 Jun 2.

8.

Assessing Bone Marrow Activity in Patients with Myelofibrosis: Results of a Pilot Study of 18F-FLT PET.

Vercellino L, Ouvrier MJ, Barré E, Cassinat B, de Beco V, Dosquet C, Chevret S, Meignin V, Chomienne C, Toubert ME, Merlet P, Kiladjian JJ.

J Nucl Med. 2017 Oct;58(10):1603-1608. doi: 10.2967/jnumed.116.188508. Epub 2017 Mar 30.

9.

Age-Associated Decrease of the Histone Methyltransferase SUV39H1 in HSC Perturbs Heterochromatin and B Lymphoid Differentiation.

Djeghloul D, Kuranda K, Kuzniak I, Barbieri D, Naguibneva I, Choisy C, Bories JC, Dosquet C, Pla M, Vanneaux V, Socié G, Porteu F, Garrick D, Goodhardt M.

Stem Cell Reports. 2016 Jun 14;6(6):970-984. doi: 10.1016/j.stemcr.2016.05.007.

10.

Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations.

Verger E, Cassinat B, Chauveau A, Dosquet C, Giraudier S, Schlageter MH, Ianotto JC, Yassin MA, Al-Dewik N, Carillo S, Legouffe E, Ugo V, Chomienne C, Kiladjian JJ.

Blood. 2015 Dec 10;126(24):2585-91. doi: 10.1182/blood-2015-07-659060. Epub 2015 Oct 20.

PMID:
26486786
11.

Hind limb unloading, a model of spaceflight conditions, leads to decreased B lymphopoiesis similar to aging.

Lescale C, Schenten V, Djeghloul D, Bennabi M, Gaignier F, Vandamme K, Strazielle C, Kuzniak I, Petite H, Dosquet C, Frippiat JP, Goodhardt M.

FASEB J. 2015 Feb;29(2):455-63. doi: 10.1096/fj.14-259770. Epub 2014 Nov 5.

PMID:
25376832
12.

Use of the 46/1 haplotype to model JAK2(V617F) clonal architecture in PV patients: clonal evolution and impact of IFNα treatment.

Hasan S, Cassinat B, Droin N, Le Couedic JP, Favale F, Monte-Mor B, Lacout C, Fontenay M, Dosquet C, Chomienne C, Solary E, Villeval JL, Casadevall N, Kiladjian JJ, Vainchenker W, Plo I.

Leukemia. 2014 Feb;28(2):460-3. doi: 10.1038/leu.2013.303. Epub 2013 Oct 22. No abstract available.

PMID:
24150219
13.

Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups.

Ianotto JC, Boyer-Perrard F, Gyan E, Laribi K, Cony-Makhoul P, Demory JL, De Renzis B, Dosquet C, Rey J, Roy L, Dupriez B, Knoops L, Legros L, Malou M, Hutin P, Ranta D, Schoenwald M, Andreoli A, Abgrall JF, Kiladjian JJ.

Br J Haematol. 2013 Sep;162(6):783-91. doi: 10.1111/bjh.12459. Epub 2013 Jul 13.

PMID:
23848933
14.

Does increasing the JAK2V617F assay sensitivity allow to identify more patients with MPN?

Kouroupi E, Kiladjian JJ, Dosquet C, Menot ML, Bonnin N, Ades L, Vainchenker W, Chomienne C, Cassinat B.

Blood Cancer J. 2012 May;2(5):e70. doi: 10.1038/bcj.2012.15. Epub 2012 May 4. No abstract available.

15.

Coexistence of a myeloproliferative disorder and secondary polycythemia in the same patient.

Kouroupi E, Cassinat B, Schlageter MH, Dosquet C, Kiladjian JJ, Chomienne C.

Am J Hematol. 2012 Jun;87(6):646. doi: 10.1002/ajh.23185. Epub 2012 Mar 31. No abstract available. Erratum in: Am J Hematol. 2012 Jul;87(7):748. Cassinat, Bruno [added]; Schlageter, Marie-Helene [added]; Dosquet, Christine [added]; Kiladjian, Jean-Jacques [added]; Chomienne, Christine [added].

16.

Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980.

Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD.

J Clin Oncol. 2011 Oct 10;29(29):3907-13. doi: 10.1200/JCO.2011.36.0792. Epub 2011 Sep 12.

PMID:
21911721
17.

The JAK2 46/1 haplotype in splanchnic vein thrombosis.

Kouroupi E, Kiladjian JJ, Chomienne C, Dosquet C, Bellucci S, Valla D, Cassinat B.

Blood. 2011 May 26;117(21):5777-8. doi: 10.1182/blood-2011-03-343657. No abstract available.

PMID:
21617012
18.

Age-related changes in human hematopoietic stem/progenitor cells.

Kuranda K, Vargaftig J, de la Rochere P, Dosquet C, Charron D, Bardin F, Tonnelle C, Bonnet D, Goodhardt M.

Aging Cell. 2011 Jun;10(3):542-6. doi: 10.1111/j.1474-9726.2011.00675.x. Epub 2011 Mar 22.

19.

β-Catenin and NF-κB cooperate to regulate the uPA/uPAR system in cancer cells.

Moreau M, Mourah S, Dosquet C.

Int J Cancer. 2011 Mar 15;128(6):1280-92. doi: 10.1002/ijc.25455.

20.

Reduced EBF expression underlies loss of B-cell potential of hematopoietic progenitors with age.

Lescale C, Dias S, Maës J, Cumano A, Szabo P, Charron D, Weksler ME, Dosquet C, Vieira P, Goodhardt M.

Aging Cell. 2010 Jun;9(3):410-9. doi: 10.1111/j.1474-9726.2010.00566.x. Epub 2010 Mar 13.

21.

Interlaboratory development and validation of a HRM method applied to the detection of JAK2 exon 12 mutations in polycythemia vera patients.

Ugo V, Tondeur S, Menot ML, Bonnin N, Le Gac G, Tonetti C, Mansat-De Mas V, Lecucq L, Kiladjian JJ, Chomienne C, Dosquet C, Parquet N, Darnige L, Porneuf M, Escoffre-Barbe M, Giraudier S, Delabesse E, Cassinat B; French Intergroup of Myeloproliferative disorders.

PLoS One. 2010 Jan 26;5(1):e8893. doi: 10.1371/journal.pone.0008893.

22.

EMMPRIN promotes angiogenesis through hypoxia-inducible factor-2alpha-mediated regulation of soluble VEGF isoforms and their receptor VEGFR-2.

Bougatef F, Quemener C, Kellouche S, Naïmi B, Podgorniak MP, Millot G, Gabison EE, Calvo F, Dosquet C, Lebbé C, Menashi S, Mourah S.

Blood. 2009 Dec 24;114(27):5547-56. doi: 10.1182/blood-2009-04-217380. Epub 2009 Oct 16.

PMID:
19837976
23.

Mutations in exon 12 of JAK2 are mainly found in JAK2 V617F-negative polycythaemia vera patients.

Kouroupi E, Zoi K, Parquet N, Zoi C, Kiladjian JJ, Grigoraki V, Vainchenker W, Lellouche F, Marzac C, Schlageter MH, Dosquet C, Scott LM, Fenaux P, Loukopoulos D, Chomienne C, Cassinat B.

Br J Haematol. 2008 Aug;142(4):676-9. doi: 10.1111/j.1365-2141.2008.07223.x. Epub 2008 May 22. No abstract available.

PMID:
18503583
24.

Strong association between plasma thrombomodulin and pathergy test in Behçet disease.

Menashi S, Tribout B, Dosquet C, Le Toumelin P, Piette JC, Wechsler B, Boffa MC.

Ann Rheum Dis. 2008 Jun;67(6):892-3. doi: 10.1136/ard.2007.075143. No abstract available.

PMID:
18474657
25.

VEGF and VEGFR-1 are coexpressed by epithelial and stromal cells of renal cell carcinoma.

Rivet J, Mourah S, Murata H, Mounier N, Pisonero H, Mongiat-Artus P, Teillac P, Calvo F, Janin A, Dosquet C.

Cancer. 2008 Jan 15;112(2):433-42.

26.

Tissue engineering for full-thickness burns: a dermal substitute from bench to bedside.

Kellouche S, Martin C, Korb G, Rezzonico R, Bouard D, Benbunan M, Dubertret L, Soler C, Legrand C, Dosquet C.

Biochem Biophys Res Commun. 2007 Nov 23;363(3):472-8. Epub 2007 Sep 4.

PMID:
17888881
27.

Platelets, thrombospondin-1 and human dermal fibroblasts cooperate for stimulation of endothelial cell tubulogenesis through VEGF and PAI-1 regulation.

Kellouche S, Mourah S, Bonnefoy A, Schoëvaert D, Podgorniak MP, Calvo F, Hoylaerts MF, Legrand C, Dosquet C.

Exp Cell Res. 2007 Feb 1;313(3):486-99. Epub 2006 Oct 28.

PMID:
17126831
28.

Relationship of circulating biomarkers of inflammation and hemostasis with preclinical atherosclerotic burden in nonsmoking hypercholesterolemic men.

Chironi G, Dosquet C, Del-Pino M, Denarie N, Megnien JL, Drouet L, Bal dit Sollier C, Levenson J, Simon A.

Am J Hypertens. 2006 Oct;19(10):1025-31.

PMID:
17027822
29.

ABO-mismatched marrow processing for transplantation: results of 114 procedures and analysis of immediate adverse events and hematopoietic recovery.

Larghero J, Rea D, Esperou H, Biscay N, Maurer MN, Lacassagne MN, Ternaux B, Traineau R, Yakouben K, Dosquet C, Socié G, Gluckman E, Benbunan M, Marolleau JP.

Transfusion. 2006 Mar;46(3):398-402.

PMID:
16533282
30.

Phase I study of high-dose topotecan with haematopoietic stem cell support in the treatment of ovarian carcinomas: the ITOV 01 protocol.

Lotz JP, Pautier P, Selle F, Viens P, Fabbro M, Lokiec F, Viret F, Gligorov J, Gosse B, Provent S, Ribrag V, Micléa JM, Dosquet C, Goetschel A, Cailliot C, Lefèvre G, Genève J, Lhommé C; Groupe d' Intensification des traitements des Tumeurs Ovariennes (ITOV Group).

Bone Marrow Transplant. 2006 Apr;37(7):669-75.

PMID:
16501591
31.

Kaposi's sarcoma-associated herpesvirus viremia is associated with the progression of classic and endemic Kaposi's sarcoma.

Pellet C, Kerob D, Dupuy A, Carmagnat MV, Mourah S, Podgorniak MP, Toledano C, Morel P, Vérola O, Dosquet C, Hamel Y, Calvo F, Rabian C, Lebbé C.

J Invest Dermatol. 2006 Mar;126(3):621-7.

32.

EBV transformation of cells from cord blood donations: relevance to future retrospective studies on cord blood transplants.

Wang XN, Dickinson AM, Douglas EA, Rae M, Fournier I, Dosquet C, Charron D, Gluckman E, Toubert A.

Bone Marrow Transplant. 2005 Mar;35(6):619-21. No abstract available.

PMID:
15665851
33.

Protective effects of basic fibroblast growth factor in early atherosclerosis.

Six I, Mouquet F, Corseaux D, Bordet R, Letourneau T, Vallet B, Dosquet CC, Dupuis B, Jude B, Bertrand ME, Bauters C, Van Belle E.

Growth Factors. 2004 Sep;22(3):157-67.

PMID:
15518239
34.

Effects of platelet lysates on select bone cell functions.

Soffer E, Ouhayoun JP, Dosquet C, Meunier A, Anagnostou F.

Clin Oral Implants Res. 2004 Oct;15(5):581-8.

PMID:
15355401
35.

Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice.

Rousselot P, Larghero J, Labaume S, Poupon J, Chopin M, Dosquet C, Marolleau JP, Janin A, Brouet JC, Fermand JP.

Eur J Haematol. 2004 Mar;72(3):166-71.

PMID:
14962234
36.

Randomized trial and local biological effect of autologous platelets used as adjuvant therapy for chronic venous leg ulcers.

Senet P, Bon FX, Benbunan M, Bussel A, Traineau R, Calvo F, Dubertret L, Dosquet C.

J Vasc Surg. 2003 Dec;38(6):1342-8.

37.

Eruptive angiomatous lesions associated with graft-versus-host disease.

Adamski H, Le Gall F, Cartron L, Dauriac C, Lancien G, Wechsler J, Ollivier I, Lachgar S, Dosquet C, Coudert MC, Chevrant-Breton J.

Br J Dermatol. 2003 Sep;149(3):667-8. No abstract available.

PMID:
14511016
38.

Wound healing mediator production by human dermal fibroblasts grown within a collagen-GAG matrix for skin repair in humans.

Froget S, Barthelemy E, Guillot F, Soler C, Coudert MC, Benbunan M, Dosquet C.

Eur Cytokine Netw. 2003 Jan-Mar;14(1):60-4.

39.

Clinical phase I and pharmacokinetic study of S 16020, a new olivacine derivative: report on three infusion schedules.

Awada A, Giacchetti S, Gerard B, Eftekhary P, Lucas C, De Valeriola D, Poullain MG, Soudon J, Dosquet C, Brillanceau MH, Giroux B, Marty M, Bleiberg H, Calvo F, Piccart M.

Ann Oncol. 2002 Dec;13(12):1925-34.

40.

Self-healing generalized infantile myofibromatosis with elevated urinary bFGF.

Léauté-Labrèze C, Labarthe MP, Blanc JF, Sanyas P, Dosquet C, Taïeb A.

Pediatr Dermatol. 2001 Jul-Aug;18(4):305-7.

PMID:
11576403
41.

Study of cord blood natural killer cell suppressor activity.

El Marsafy S, Dosquet C, Coudert MC, Bensussan A, Carosella E, Gluckman E.

Eur J Haematol. 2001 Apr;66(4):215-20.

PMID:
11380600
42.

Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors?

Tabone MD, Landman-Parker J, Arcil B, Coudert MC, Gerota I, Benbunan M, Leverger G, Dosquet C.

Clin Cancer Res. 2001 Mar;7(3):538-43.

43.

Cytokines and vascular cell adhesion molecule-1 in the blood of patients undergoing HPC mobilization.

Dosquet C, Chen Y, Makke J, Miclea JM, Coudert MC, Marolleau JP, Fermand JP, Cottu P, Lotz JP, Benbunan M.

Transfusion. 2001 Feb;41(2):206-12.

PMID:
11239224
44.

[Cell therapy: perspectives for curing skin wounds?].

Senet P, Coulomb B, Benbunan M, Meaume S, Dubertret L, Dosquet C.

Ann Dermatol Venereol. 2000 Aug-Sep;127(8-9):765-6. French. No abstract available.

PMID:
11011176
45.

Human platelet suspension stimulates porcine retinal glial proliferation and migration in vitro.

Castelnovo L, Dosquet C, Gaudric A, Sahel J, Hicks D.

Invest Ophthalmol Vis Sci. 2000 Feb;41(2):601-9.

PMID:
10670494
46.

Effect of autologous platelet concentrate in surgery for idiopathic macular hole: results of a multicenter, double-masked, randomized trial. Platelets in Macular Hole Surgery Group.

Paques M, Chastang C, Mathis A, Sahel J, Massin P, Dosquet C, Korobelnik JF, Le Gargasson JF, Gaudric A.

Ophthalmology. 1999 May;106(5):932-8.

PMID:
10328392
47.

Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?

Dosquet C, Coudert MC, Lepage E, Cabane J, Richard F.

Clin Cancer Res. 1997 Dec;3(12 Pt 1):2451-8.

48.

[Importance of bFGF ("basic fibroblast growth factor") for diagnosis and treatment of hemangiomas].

Dosquet C, Coudert MC, Wassef M, Enjolras O, Drouet L.

Ann Dermatol Venereol. 1998 May;125(5):313-6. French.

49.

[Kasabach-Merritt syndrome on a congenital tufted angioma].

Enjolras O, Wassef M, Dosquet C, Drouet L, Fortier G, Josset P, Merland JJ, Escande JP.

Ann Dermatol Venereol. 1998 Apr;125(4):257-60. French.

PMID:
9747263
50.

Studies of portal hemodynamics and hepatic oxygen consumption during acute liver allograft rejection.

Gadano A, Durand F, Degott C, Dosquet C, Moreau R, Hadengue A, Widmann JJ, Vachiery F, Elman A, Sogni P, Yang S, Valla D, Bernuau J, Belghiti J, Erlinger S, Lebrec D.

Transplantation. 1997 Oct 27;64(8):1188-92.

PMID:
9355838

Supplemental Content

Loading ...
Support Center